TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

DEFINITY RT

PERFLUTREN Ultrasound Contrast Activity
Approved 2001-07-31
3
Indications
--
Phase 3 Trials
24
Years on Market

Details

Status
Prescription
First Approved
2001-07-31
Routes
INTRAVENOUS
Dosage Forms
INJECTABLE

Companies

Active Ingredient: PERFLUTREN

DEFINITY RT Approval History

Loading approval history...

What DEFINITY RT Treats

1 indications

DEFINITY RT is approved for 1 conditions since its original approval in 2001. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Suboptimal Echocardiograms
Source: FDA Label

DEFINITY RT Boxed Warning

SERIOUS CARDIOPULMONARY REACTIONS Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following perflutren-containing microsphere administration. Most serious reactions occur within 30 minutes of administration. Assess all patients for the presence of any condition that precludes DEFINITY RT administration [see Contraindications (4) ] . Always have resuscitation equipment and trained personnel readily available [see Warnings and Precautions (5.1) ] . WARNI...

Drugs Similar to DEFINITY RT

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

๐Ÿ”ฌ

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
โญ

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
๐Ÿ“Š

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

DEFINITY RT FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

DEFINITY RT is indicated, after activation, for use in adult and pediatric patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border. DEFINITY RT is an ultrasound contrast agent indicated, after activation, for use in adult and pediatric patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.

โš ๏ธ BOXED WARNING

WARNING: SERIOUS CARDIOPULMONARY REACTIONS Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following perflutren-containing microsphere administration. Most serious reactions occur within 30 minutes of administration. Assess all patients for the presence of...

DEFINITY RT Patents & Exclusivity

Latest Patent: May 2037

Patents (20 active)

US10588988 Expires May 4, 2037
US9789210 Expires Mar 16, 2037
US10583208 Expires Mar 16, 2037
US11925695 Expires Mar 16, 2037
US11529431 Expires Mar 16, 2037
US11857646 Expires Mar 16, 2037
US11266750 Expires Mar 16, 2037
US12161730 Expires Mar 16, 2037
US10583207 Expires Dec 28, 2035
US11395856 Expires Dec 28, 2035
+ 10 more patents
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.